 |
 |
This discussion has been interesting, and also disturbing. From what Dr. Romero wrote about rasagiline, it seems to me that all these newly announced clinical trials are likely to be a waste of time and effort for the clinicians and patients involved- for a new drug that doesn't offer any benefits over what is already available. And the even the currently available drug may be of questionable value itself. What will these trials do to advance PD research and treatment? It seems very disappointing. This is what also concerns me about the limits on federal funding of stem cell research. We're told the drug companies will continue their research anyway, but can we trust that their research will be in the best interest of patients hoping for a cure? Linda ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn